Biotech Values

[DewDiligence]

Another boneheaded comment in a biotech write-up:

http://www.bioworld.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=46709

“The Phase III program falls in line with Vertex's
plan, disclosed earlier. In the larger study, patients
need to hit RVR at 4 weeks in order to qualify for
stopping at the 24th week, and the test is mainly
designed to show a 15 percent difference in the
SVR between drug and placebo at week 24.”

LOL—not exactly.